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Prevalent mutator genotype identiﬁed in fungal
pathogen Candida glabrata promotes multi-drug
resistance
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The fungal pathogen Candida glabrata has emerged as a major health threat since it readily
acquires resistance to multiple drug classes, including triazoles and/or echinocandins. Thus
far, cellular mechanisms promoting the emergence of resistance to multiple drug classes have
not been described in this organism. Here we demonstrate that a mutator phenotype caused
by a mismatch repair defect is prevalent in C. glabrata clinical isolates. Strains carrying
alterations in mismatch repair gene MSH2 exhibit a higher propensity to breakthrough
antifungal treatment in vitro and in mouse models of colonization, and are recovered at a high
rate (55% of all C. glabrata recovered) from patients. This genetic mechanism promotes the
acquisition of resistance to multiple antifungals, at least partially explaining the elevated
rates of triazole and multi-drug resistance associated with C. glabrata. We anticipate that
identifying MSH2 defects in infecting strains may inﬂuence the management of patients on
antifungal drug therapy.
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C
andida species account for the most mucosal and invasive
fungal infections worldwide1 and are the fourth leading
cause of nosocomial bloodstream infections in the
United States2. Candida bloodstream infections cause estimated
healthcare costs of $2–4 billion per year in the United States alone
and are associated with a crude mortality rate of 40%, even with
antifungal treatment1. The current arsenal of antifungal drugs is
limited, with only two non-toxic antifungal classes to treat
candidiasis: triazoles (for example, ﬂuconazole and voriconazole)
and echinocandins (for example, caspofungin and micafungin).
Polyenes, such as amphotericin B formulations, represent a third
class of antifungals, but polyene use is more restricted due to
nephrotoxicity3. Although 50% of worldwide candidemia cases
are caused by C. albicans, there has been a steady shift towards
non-albicans species over the past 20 years1,4. In North America,
C. glabrata now accounts for B25% of Candida infections4,5.
Albeit this species lacks some important Candida virulence
factors, including hyphal formation, between 20 and 30% of
C. glabrata strains exhibit triazole resistance, and this number
continues to rise6,7. C. glabrata has also developed resistance to
the echinocandins, which were introduced into the market less
than 15 years ago, at a faster rate than any other Candida
species6. Depending on the study and geographical location,
between 3 and 12% of C. glabrata isolates now demonstrate
resistance to one or more echinocandin6,8. Alarmingly, multi-
drug resistant (MDR) C. glabrata6,8–12, which exhibit resistance
to two or more classes of antifungal drugs, are commonly
encountered leaving virtually no options for treatment.
Different antifungal drug classes have distinct targets and
mechanisms of action and resistance13, and it is unclear why
C. glabrata is capable of rapidly acquiring resistance to multiple
drug classes. The acquisition of resistance frequently observed
with C. glabrata has historically been ascribed to its haploid
genome. We hypothesized that a defect in DNA repair may
account for accelerated emergence of various genetic changes
responsible for drug resistance. Normally, DNA repair is
responsible for correcting errors made by DNA polymerase
during DNA replication, as well as for repairing DNA damage
caused by environmental factors, such as chemicals or radiation,
or by endogenous factors, such as reactive oxygen radicals. Thus
far, the role of DNA repair in fungal pathogens, especially in the
emergence of antifungal resistance, has not been explored in
depth.
Here we focused on the role of two DNA repair pathways in
C. glabrata—mismatch repair (MMR) and double-strand break
repair (DSBR)—because defects in these pathways in bacteria14
(in vitro and in vivo) and C. albicans15 (in vitro) have been shown
to lead to a hyper-mutable phenotype. More speciﬁcally,
homozygous disruption of DSBR gene RAD50 and MMR genes
MSH2 and PMS1 in C. albicans led to an elevated frequency of
ﬂuconazole-resistant colonies15; therefore, we began our studies
examining homologous genes in C. glabrata. We found that
disruption of MSH2 in C. glabrata led to a hyper-mutable
phenotype and signiﬁcant increases in the emergence of
antifungal resistant mutants. Nonsynonymous mutations
discovered within MSH2 in over half (195 out of 357) of the
clinical strains analyzed produced similar phenotypes. Our data
suggest that defects in mismatch repair represent a key,
underlying cellular mechanism that facilitates emergence of
resistance to multiple antifungals in C. glabrata.
Results
MSH2 deletion leads to an increase in resistant mutants. To
determine the effects of DNA MMR and DSBR on C. glabrata
antifungal resistance, we separately disrupted one MMR
gene, MSH2 (CAGL0I07733g) and one DSBR gene, RAD50
(CAGL0J07788g). Echinocandin and ﬂuconazole minimum
inhibitory concentrations (MICs) were not signiﬁcantly changed
(o2-fold) in the disruptants when compared with the wild type
parental strain (Supplementary Table 1). However, subsequent
antifungal selections revealed that the msh2D strains generated
B82-, 18- and 9-fold more caspofungin-, ﬂuconazole- and
amphotericin B-resistant mutants, respectively, when compared
with the wild type strain (Fig. 1). The rad50D strain did not affect
antifungal resistance frequencies as strongly (2 to 5-fold increases
relative to wild type). The msh2D strain also exhibited
increased resistance frequencies to micafungin and voriconazole
(Supplementary Fig. 1). Over 90% of echinocandin- (caspofungin
and micafungin) selected colonies displayed high-level resistance
(MICs42 mgml 1) and 100% of those resistant msh2D colonies
(25/25) displayed a hotspot mutation in either Fks1 or Fks2
(Table 1). Fks1/2 hotspot mutations represent the primary
mechanism of echinocandin clinical resistance16. C. glabrata
triazole resistance arises most commonly through overexpression
of drug efﬂux pumps, which is achieved through gain-of-function
mutation of the transcription factor Pdr1 (refs 17,18). As expected,
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Figure 1 | Deletion of MSH2 in C. glabrata leads to signiﬁcantly more resistant colonies upon selection on multiple antifungal drugs. Wild type, msh2D
and rad50D strains were selected on media containing caspofungin (an echinocandin), ﬂuconazole (a triazole) and amphotericin B (a polyene) at
concentrations from 16- to 32-fold greater than wild type MICs as described in Methods section. The plots show means of resistant colony frequencies
from Z3 independent experiments±s.d. See Supplementary Fig. 1 for resistant frequencies to voriconazole (triazole) and micafungin (echinocandin).
**Po0.01 (student’s t-test; two-tailed). Representative images of selection plates are shown. Scale bars¼ 1 cm.
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pdr1 mutations were identiﬁed in 10 of 14 ﬂuconazole-resistant
wild type and msh2D mutants (Table 1). Likewise, an erg6
mutation (Erg6-K157fs) was identiﬁed in one amphotericin
B-resistant mutant from msh2D selections (Table 1). Compared
with triazoles and echinocandins, molecular mechanisms of
polyene resistance are less well described in C. glabrata; however
mutations in speciﬁc ERG genes, including ERG6 have been
associated with polyene reduced susceptibility19,20. These data
show that defects in MMR facilitate the emergence of
mechanistically diverse C. glabrata antifungal drug resistance
in vitro.
msh2 mutations identiﬁed in diverse clinical isolates. To
investigate whether defects in MMR contribute to emergence of
antifungal resistance in the clinic, we acquired 357 geographically
diverse C. glabrata strains, including 66 from Duke Hospital
(Durham, NC), 118 from the Centers for Disease Control
(Atlanta, GA), 25 from MD Anderson Cancer Center (Houston,
TX), 18 from Wayne State University Medical School (Detroit,
MI), 40 from the University Hospital at Lausanne (Switzerland),
74 from Hamad Medical Corporation (Qatar) and 17 mis-
cellaneous strains from the laboratory collection of one of the
authors (D.S.P.). MSH2 was sequenced in all strains. Overall,
55% of these strains contained a nonsynonymous mutation
within Msh2 when compared with the database strain,
CBS138/ATCC2001 (http://www.candidagenome.org/). We fur-
ther assigned these strains into one of four categories: suscep-
tible, ﬂuconazole-resistant (ﬂuconazoleR), echinocandin-resistant
(echinocandinR) or MDR (both ﬂuconazoleR and echinocandinR).
Resistant MICs were deﬁned according to the standards
recommended by the Clinical and Laboratory Standards Institute
(CLSI)21,22. We do note that although a ﬂuconazole MIC of
32 mgml 1 is deﬁned as susceptible dose dependent, we included
these isolates in the ﬂuconazoleR group. Seventy-four out of the
81 ﬂuconazoleR-classiﬁed isolates sequenced (all groups except
Hamad Medical Corporation) contained a Pdr1 mutation
(Supplementary Data 1). Single mutations of speciﬁc amino
acids in Pdr1, including V329, N768, P927 and T1080, were
identiﬁed in both clinical isolates and lab-generated mutants
(Table 1 and Supplementary Data 1). Echinocandin resistance
was declared if an isolate demonstrated a resistant MIC to at least
two of the three echinocandin drugs. Forty-ﬁve of the 47
echinocandinR-classiﬁed isolates (echinocandinR and MDR
groups) contained an Fks1 or Fks2 hotspot mutation
(Supplementary Data 1). Out of the 357 clinical strains
analyzed, 52% (117/225) of susceptible isolates demonstrated a
nonsynonymous mutation within Msh2, while a mutation was
discovered in 65% of ﬂuconazoleR isolates (54/83; Po0.05 versus
Table 1 | Mutation or disruption of MSH2 leads to increases in resistance-conferring mutations.
Strain Selection (lgml 1) Resistant colony
frequency
average±s.d.*
Fold change
in frequency
from WT
Resistant
colonies/
total tested
Mutation
identiﬁed/
total
sequenced
Protein mutation
(nucleotide change)
Wild type Caspofungin 1 6.57E-09±3.95E-09 1 2/6 1/2 Fks2-658delF
Micafungin 0.25, 0.4 6.66E-09±1.01E-24 1 — — (1971_1973delCTT)
msh2D Caspofungin 1 5.73E-07±2.67E-07 82 9/11 9/9 Fks1-S629P (t1885c)
Micafungin 0.25, 0.4 1.46E-07±5.02E-08 22 28/28 16/16 Fks1-S629P (t1885c)
Fks1-625delF
(1875_1877delCTT)
Wild type Fluconazole 256, 512 1.59E-04±1.99E-04 1 4/6 4/6 Pdr1-N768D (a2302g)
Voriconazole 10, 30 2.22E-06±1.91E-06 1 — — Pdr1-D876Y (g2626t)
Pdr1-D926G (a2777g)
Pdr1-P927L (c2780t)
msh2D Fluconazole 256, 512 2.88E-03±1.24E-03 18 6/8 6/8 Pdr1-N283D (a847g)
Voriconazole 10, 30 2.99E-05±4.81E-06 13.5 — — Pdr1-V329F (g985t)
Pdr1-S391L (c1172t)
Pdr1-S947L (c2840t)
Pdr1-K949E (a2845g)
Pdr1-T1080I (c3239t)
Wild type Amphotericin B 2, 3 5.71E-06±4.92E-06 1 5/11 0/5 —
msh2D Amphotericin B 2, 3 5.43E-05±9.55E-06 9.5 3/15 1/3 Erg6-K157fs (470delT)
Clinical isolate 1
(Msh2-P208S/N890I)
Caspofungin 1 5.41E-07±1.34E-08 82w 6/11 5/6 Fks2-658delF
(1971_1973delCTT)
Fks2-L662W (t1985g)
Clinical isolate 2
(Msh2-P208S/N890I)
Caspofungin 1 5.64E-07±1.98E-08 29w 6/11 1/6 Fks2-S663P (t1987c)
msh2Dþ pMSH2-wt Caspofungin 1 9.13E-08±4.07E-08 1 1/5 0/1 —
msh2Dþ empty plasmid Caspofungin 1 5.63E-07±5.48E-08 6.2 5/5 3/3 Fks2-S663P (t1987c)
Fks2-S663Y (c1988a)
Fks2-S663F (c1988t)
msh2Dþ pMSH2-P208S/N890I Caspofungin 1 5.95E-07±2.19E-07 6.5 5/5 2/3 Fks1-S629P (t1885c)
msh2Dþ pMSH2-V239L Caspofungin 1 5.63E-07±8.83E-08 6.2 5/6 1/3 Fks1-S629P (t1885c)
msh2Dþ pMSH2-E231G/L269F Caspofungin 1 3.45E-07±1.34E-07 3.8 4/10 1/4 Fks2-S663F (c1988t)
msh2Dþ pMSH2-L269F Caspofungin 1 3.20E-07±1.91E-08 3.5 6/6 5/6 Fks1-S629P (t1885c)
*Resistant colony frequency averages calculated from selections of all indicated concentrations. A minimum of three independent selections per strain were performed (1–5 selections per concentration).
wClinical isolate fold change compared to the non-isogenic wild type strain.
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susceptible, w2¼ 4.1879) and 62% of MDR isolates (21/34; ns
versus susceptible, w2¼ 1.1314) (Fig. 2a,b). We did ﬁnd individual
center differences. For example, strains from Duke Hospital
exhibited similar levels of msh2 mutations in susceptible (53%),
ﬂuconazoleR (46%) and MDR isolates (50%) (Fig. 2b), whereas
isolates obtained from other centers (MD Anderson Cancer
Center and University Hospital at Lausanne) demonstrated a
pattern consisting of lower levels of mutations in susceptible
isolates (29 and 52%) compared with ﬂuconazoleR isolates
(100 and 73%, both respectively) (Fig. 2b). The only center that
provided non-blood stream isolates, Wayne State University
Medical School, demonstrated high levels of msh2 mutations in
both susceptible and ﬂuconazoleR isolates (78% each). These
vaginal isolates were obtained from patients with recurrent
vaginitis. We found a low percentage of msh2 mutations in
echinocandinR isolates, although fewer of these isolates were
obtained (Fig. 2b). Overall, these data revealed that
polymorphisms in the MSH2 gene are present in an
unexpectedly high percentage of clinical C. glabrata isolates,
particularly ﬂuconazoleR strains.
To better understand the timeline of appearance of these msh2
polymorphisms, we obtained and analyzed paired sets of isolates
from the participating centers. Each pair (or triplet) of isolates
was isolated from the same patient. Out of these 30 sets of
isolates, 20 contained an msh2 mutation in at least one isolate
(Table 2). In all but three sets of isolates that contained an
alteration, the identiﬁed mutation was present in all isolates from
that patient, independent of the susceptibility, suggesting that the
msh2 mutation predated the emergence of ﬂuconazole and/or
echinocandin resistance in these patients. Interestingly, in the
remaining three sets (all from a single center), we identiﬁed
differences in Msh2 within isolates taken from the same patient
(Table 2). In each case, an msh2 mutation or additional
mutation(s) was only identiﬁed within the second, ﬂuconazoleR
isolate (Table 2).
Notably, 96% of msh2 mutations in the analyzed
clinical isolates contained the following amino acid changes:
P208S/N890I, E231G/L269F, V239L/A942T or V239L (see
Supplementary Data 1). These amino acids (P208, E231, V239
and L269) map to the protein’s connector region, which is
essential for interaction between the MutS (Msh2-Msh3/6) and
MutL (Pms1-Mlh1) complexes and therefore, MMR activity23.
Indeed, upon caspofungin selection in vitro, echinocandin
susceptible clinical isolates containing these msh2 mutations
produced signiﬁcantly higher frequencies of echinocandinR
colonies and fks mutants than isolates carrying wild type MSH2
(Fig. 2c and Table 1). To directly analyze the functionality of the
most commonly identiﬁed msh2 mutations, alleles were ampliﬁed
from clinical isolates, expressed on a yeast centromere plasmid
under the control of their native promoter, and transformed into
a laboratory strain carrying a deletion of MSH2. Forward
mutation frequencies were analyzed by measuring frequencies
of colonies resistant to the echinocandin caspofungin (largely due
to mutations in FKS1 or FKS2) or to 5-ﬂuoroanthranilic acid
(5-FAA; largely due to mutations in TRP3 or TRP5)24.
As expected, we found that msh2D exhibited a hyper-mutable
phenotype (average caspofunginR colony frequency¼
5.63 10 7, average 5-FAAR colony frequency¼ 5.32 10 4;
Fig. 2d). While MSH2 derived from a wild type strain or from a
clinical isolate containing one conservative mutation (E456D)
complemented the msh2Dmutant phenotype, expression of either
msh2-P208S/N890I, msh2-V239L or msh2-E231G/L269F did not
complement msh2D: the plasmid-borne msh2 alleles produced the
high frequencies of echinocandinR and 5-FAAR colonies
characteristic of the msh2D mutant (Fig. 2d). The resulting
echinocandinR colonies contained Fks mutations, speciﬁcally
fks1-S629P, fks2-S663P, fks2-S663Y and fks2-S663F (Table 1), all
of which have been previously shown to lead to echinocandin
treatment failure25–27. Also, B25% of the 5-FAAR colonies
contained trp3 nonsynonymous mutations (Supplementary
Table 2). Together, these data suggest that clinical strains of C.
glabrata carry mutations in MSH2, which result in MMR defects
and promote the emergence of antifungal resistance.
Colonization with msh2D leads to increased resistance in vivo.
To determine if altered MMR activity can promote the develop-
ment of C. glabrata antifungal resistance in vivo, we utilized a
mouse model of C. glabrata gastrointestinal (GI) colonization
(Fig. 3a). This model recapitulates pathogenesis of human disease
through overgrowth of yeast in the primary reservoir (GI). First,
bacterial ﬂora were eradicated from the GI tract with a daily
piperacillin-tazobactam (PTZ) regimen28 (Fig. 3a). Mice were
then orally inoculated with either a wild type or msh2D strain
followed by daily, sub-inhibitory echinocandin (caspofungin;
0.5mg kg 1 i.p.) or vehicle (saline i.p.) administration for 21
days. Mice were effectively colonized (range: 5 107 to 1 108
CFU per gram of stool) with both the wild type and msh2D
strains from days 1 to 27 post-inoculation (Fig. 3a). Of note, no
signiﬁcant growth difference between these strains in vitro was
observed (Supplementary Fig. 2). Caspofungin resistant colony
frequencies from each mouse were tracked at one time point prior
to and four time points following treatment initiation over a
period of 18 days. While we observed no increases in resistant
yeast recovered from eight caspofungin-treated mice that were
colonized with the wild type strain, ﬁve of eight caspofungin-
treated mice that were colonized with the msh2D strain
demonstrated an increase in resistant colonies 6 to 12 days
following treatment initiation, representative of an expanding fks
mutant population (Fig. 3b). DNA sequencing revealed that
echinocandin resistance was due to fks1 mutations in yeast
recovered from those mice (Fig. 3c). This suggests that loss of
MMR in C. glabrata can lead to an increased frequency of
resistance-conferring mutations in vivo.
Fitness of msh2D assayed in mixed inoculation mouse models.
In patients, strains containing defects in MMR may coexist with
strains with wild type MMR function. Therefore, we performed
ﬁtness assays using both the aforementioned GI colonization
model, as well as a systemic infection mouse model to assess the
ﬁtness of a MMR-deﬁcient strain in vivo (see Methods section for
details). Mice were inoculated with either wild type, msh2D, or an
equal CFU mix of both strains. In the systemic model, kidneys
were harvested at day 3 post-infection and subject to CFU plating
and qPCR analysis following DNA isolation. Speciﬁc primers
were designed for both wild type and msh2D strains
(Supplementary Table 3). SYBR green real-time PCR was used to
quantify DNA copy number and calculate strain ratios. Similarly,
fecal samples collected from colonized mice at day 1, 3, 5, 7, 9 and
11 post-inoculation were assessed for mixed population ratio. In
the systemic infection model, the average wild type to mutant
ratio found in kidneys isolated from mice infected with both
strains was 2:1 (Fig. 4a), indicating a modest ﬁtness defect of the
msh2D strain. Similarly, we found an increasing wild type to
mutant ratio in fecal samples over the course of the colonization
model (Fig. 4b). Importantly, both models demonstrated similar
levels of colonization and infection when inoculated with either
wild type or msh2D alone (Supplementary Fig. 3).
Discussion
While antifungal drug resistance is nearly always due to fungal
genome alterations ranging from point mutations to gain or loss
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of whole chromosomes13, the identity of speciﬁc DNA repair
pathways that impinge on the emergence of C. glabrata resistance
has remained unknown. Here, we have shown that an
unexpectedly high percentage (55%) of clinical C. glabrata
isolates carry loss-of-function mutations in the MMR gene
MSH2, which produced a mutator phenotype resulting in
accelerated emergence of antifungal drug resistance both
in vitro and in vivo. Interestingly, these mutations were more
frequent among ﬂuconazoleR and MDR C. glabrata isolates
(Fig. 2a), suggesting that their appearance may be associated with
ﬂuconazole exposure. While msh2 mutations were also found in
nearly half of all drug susceptible isolates, we must emphasize that
many patients were severely ill and had most likely been exposed
to multiple drugs, including antibiotics, steroids, antineoplastics
and/or antifungals, which may have also inﬂuenced the frequency
of msh2 mutations. Differences in patient populations and
antifungal administration practices are likely responsible for the
signiﬁcant discrepancies observed in the frequencies of msh2
mutations in susceptible and resistant isolates across different
institutions (Fig. 2a,b).
The lower percentage of msh2 mutations identiﬁed in
echinocandinR clinical isolates may be due to a small number
of such strains available for analysis. Alternatively, we cannot
exclude a negative genetic interaction between defects in MMR
Center Susceptible FLC-R ECH-R MDR
MD Anderson Cancer Center 4/14 (29) 9/9 (100) 0/1 (0) 0/1 (0)
Univ. Hospital Lausanne 13/25 (52) 11/15 (73) – –
Hamad Med. Corp. 21/38 (55) 20/34 (59) – 2/2 (100)
Duke Hospital 19/36 (53) 6/13 (46) 2/8 (25) 4/8 (50)
Centers for Disease Control 52/99 (53) 0/2 (0) – 9/17 (53)
Wayne State Univ. 7/9 (78) 7/9 (78) – –
Miscellaneous 1/4 (25) 1/1 (100) 1/6 (17) 6/6 (100)
TOTAL 117/225 (52) 54/83 (65) 3/15 (20) 21/34 (62)
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Figure 2 | Msh2 alterations identiﬁed in diverse clinical isolates cause a mutator phenotype and increased emergence of antifungal resistance.
(a) The 357 clinical isolates obtained were classiﬁed according to their susceptibilities to ﬂuconazole (FLC) and the echinocandins (ECH), and the
percentage of isolates within each group demonstrating a nonsynonymous msh2 mutation were determined. P value was determined through w2 analysis
(compared with susceptible group). (b) All isolates were categorized by institution. Isolates demonstrating an msh2 mutation/total isolates are shown for
each susceptibility group. See Supplementary Data 1 for a list of all individual isolates analyzed. (c) Echinocandin- (caspofungin) resistant colony
frequencies of various clinical isolates were measured. (d) Wild type or msh2D cells expressing an empty or MSH2-containing plasmid were selected on
caspofungin and 5-ﬂuoroanthranilic acid. See Supplementary Table 4 for strains. Frequency data in c,d are mean±s.d. from three independent experiments;
representative images are shown. *Po0.05, **Po0.01 (student’s t-test; two-tailed). Scale bars¼ 1 cm.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11128 ARTICLE
NATURE COMMUNICATIONS | 7:11128 | DOI: 10.1038/ncomms11128 | www.nature.com/naturecommunications 5
Table 2 | Paired patient isolates containing msh2 mutations.
Strain* Susceptibility Msh2 Pdr1 gain-of-functionw Fks1/2 hotspots
UHL 2270 Susceptible Wild type Wild type —
UHL 2271 FLC-R V239L D261G —
UHL 2256 Susceptible E456Dz Wild type —
UHL 2257 FLC-R V239L N691D —
UHL 2247 Susceptible V239L G493D —
UHL 2248 FLC-R V239L/K814E/A942T E1083Q —
UHL 2267 Susceptible V239S/A942T - —
UHL 2266 Susceptible V239S/A942T Wild type —
UHL 2268 FLC-R V239S/A942T S316I —
UHL 2272 Susceptible V239L/A942T Wild type —
UHL 2273 FLC-R V239L/A942T R293I —
UHL 2276 Susceptible V239L/A942T Wild type —
UHL 2277 FLC-R V239L/A942T R592S —
UHL 2278 Susceptible V239L/A942T Wild type —
UHL 2279 FLC-R V239L/A942T G583S —
UHL 529 Susceptible V239L/A942T Wild type —
UHL 530 FLC-R V239L/A942T E1083Q —
UHL 753 Susceptible V239L/A942T Wild type —
UHL 2311 Susceptible V239L/A942T Wild type —
UHL 2312 FLC-R V239L/A942T Y584C —
UHL 2280 Susceptible V239L/A942T — —
UHL 2281 Susceptible V239L/A942T — —
UHL 2282 FLC-R V239L/A942T — —
UHL 2298 Susceptible V239L/A942T — —
UHL 2299 Susceptible V239L/A942T — —
WSU 162-11 FLC-R E231G/L269F R295G —
WSU 659-11 FLC-R E231G/L269F R265G —
WSU 86-14 FLC-R E231G/L269F E340G —
WSU 339-14 Susceptible E231G/L269F E340G —
WSU 599-02 Susceptible V239L Wild type —
WSU 906-05 FLC-R V239L D1082G —
WSU 961-00 FLC-R V239L/A942T R792stop —
WSU 057-02 FLC-R V239L/A942T R792stop —
WSU 880-03 Susceptible E231G/L269F — —
WSU 847-10 Susceptible E231G/L269F — —
WSU 1080-10 Susceptible Q259H — —
WSU 584-14 Susceptible Q259H — —
Duke 299 Susceptible E231G/L269F Wild type Wild type
Duke 307 ECH-R E231G/L269F Wild type Fks2-S663P
Duke 246 FLC-R P208S/N890I G1079R Wild type
Duke 249 MDR P208S/N890I G1079R Fks2-S663P
SK 1 FLC-R V239L L825P Wild type
SK 2 MDR V239L L825P Fks2-I660_L661insF
*UHL: University Hospital at Lausanne, WSU: Wayne State University, Duke: Duke University, SK: gift of Soo-Hyun Kim (Miscellaneous group).
wCommon polymorphisms identiﬁed in both sensitive and resistant isolates not included.
zE456D does not signiﬁcantly alter MSH2 activity (see Fig. 2).
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and fks1/2 mutations, resulting in a ﬁtness defect. Fks1-S629P was
the primary mutation identiﬁed from the stool of echinocandin-
treated mice colonized with msh2D (Fig. 3c), and the most
frequent fks1 mutation among C. glabrata MDR clinical isolates
with MMR defects (Supplementary Data 1). Whether this
mutation is associated with MDR and/or inﬂuences C. glabrata
ﬁtness remains to be investigated. The equivalent C. glabrata
mutation in Fks2 (S663P) was recently shown to limit the
macrophage inﬂammatory response upon caspofungin exposure,
suggesting certain fks mutations have a higher propensity for
immune evasion29, similar to pdr1 mutations30.
The observation that only a limited spectrum of msh2
mutations were recovered from a large and diverse patient
population may indicate that these mutations did not arise de
novo in different patients, but that they pre-existed and were
enriched for during drug treatment or pathogenesis (that is
conversion from colonizer to infectious strain), perhaps by
conferring a selective advantage under those conditions. This
hypothesis is consistent with reports indicating that a mutator
phenotype may be advantageous for fungal microevolution and
survival within the host31. Also, the scenario where C. glabrata
strains defective in MMR coexist with wild type strains in the host
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Figure 3 | Colonization with msh2D leads to increased echinocandin-resistance in vivo. (a) GI colonization of CF-1 mice represented through fecal
C. glabrata burdens. Daily administration (i.p.) of caspofungin (CSF; 0.5mgml 1) or saline occurred from days 6 to 26 post-inoculation. (CSF-treated
groups: n¼ 8 wild type inoculated mice, 8 msh2D inoculated mice; Saline-treated groups: n¼ 2 wild type, 2 msh2D). Means±s.d. are calculated.
(b) Fecal samples from each mouse at days 3, 9, 12, 15 and 18 ( 3, 3, 6, 9 and 12 days post-treatment initiation, respectively) were selected on
caspofungin (2mgml 1) containing YPD media (see Methods section for additional details). Five of eight CSF-treated mice that were inoculated with
msh2D demonstrated increase in resistant colony frequencies between days 12 and 18. (c) fks1 mutants identiﬁed within fecal isolates. Colonies on
antifungal-free plates (produced in part a) were replica plated onto caspofungin-containing media. Hotspot regions of FKS1 and FKS2 (echinocandin
drug targets) were ampliﬁed and sequenced in resistant colonies.
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Figure 4 | Wild type cells partially outcompete msh2D in mixed inoculation mouse models. DNA was isolated from kidney tissue of systemically
infected, immunosuppressed mice (a) and from fecal samples of GI-colonized, immune competent mice (b) and then subjected to SYBR green quantitative
PCR with strain speciﬁc primers. Wild type (WT) to mutant ratios were calculated from qPCR DNA copy numbers. Means±s.d. are calculated.
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is consistent with our observation that the msh2D strain had only
a mild ﬁtness disadvantage in vivo when present together with the
wild type strain (Fig. 4). This ﬁtness defect may result from the
accumulation of mutations in essential genes; however, in single
challenge studies, the msh2D strain exhibited comparable or
slightly higher levels of colonization and infection relative to wild
type (Supplementary Fig. 3). Indeed, given that over half of our
patient samples, including nearly half of all susceptible isolates,
contain msh2 loss-of-function mutations, we suspect msh2
mutant colonizing strains have adapted well to their host,
possibly though acquisition of gain-of-ﬁtness mutations (for
example, pdr1 mutation32).
Previously described fungal mechanisms of genetic
instability that generate genetic diversity under stress have
primarily involved gross chromosomal rearrangements and/or
aneuploidy33. In contrast, our study presents the ﬁrst example of
a clinical, fungal population carrying a mutator phenotype due to
genetic defects in a speciﬁc DNA repair pathway, namely MMR.
It is possible that this mechanism of genetic instability is speciﬁc
to C. glabrata because, unlike the other prevalent Candida species
(C. albicans, C. parapsilosis, C. tropicalis and C. krusei),
C. glabrata is a haploid organism where a single DNA repair
mutation is sufﬁcient to cause an associated mutator phenotype
and subsequent emergence of resistance-conferring mutation(s).
We suggest that the elevated levels of both triazole and multi-
drug resistance associated with C. glabrata are at least partially
due to the presence of msh2 mutations. Based on our results, by
the time a patient requires administration of an antifungal, there
is a substantial chance that the infecting strain contains an msh2
mutation. Therefore, we propose that C. glabrata MSH2 may be
used as a biomarker prior to and throughout the course of
therapy to determine the propensity of any given C. glabrata
isolate to generate drug-resistant mutants and break through
antifungal treatment. Thus, our study may have implications for
antifungal prophylaxis, recurrent and long-term therapies, and
antifungal stewardship protocols.
Methods
Ethics statement. Mice were housed in Public Health Research Institute’s Animal
Biosafety Level-2 Research Animal Facility (ICPH RAF), a center of the New Jersey
Medical School, Rutgers University (NJMS-Rutgers). Our animal facility follows
the Public Health Service and National Institute of Health Policy of Humane Care
and Use of Laboratory Animals. All experimental protocols were approved by the
Rutgers Institutional Animal Care and Use Committee (IACUC).
Strains and media. A total of 357 C. glabrata clinical strains were obtained from
patients with C. glabrata bloodstream or vaginal infections, including 66 from
Duke Hospital (Durham, NC), 118 from the Centers for Disease Control (Atlanta,
GA, USA), 25 from MD Anderson Cancer Center (Houston, TX, USA), 18 from
Wayne State University Medical School (Detroit, MI, USA), 40 from the University
Hospital at Lausanne (Switzerland), 74 from Hamad Medical Corporation (Qatar)
and 17 additional miscellaneous strains from the laboratory collection of one of the
authors (D.S.P.). Miscellaneous strains were obtained from the American Type
Culture Collection (ATCC), Seongmin Lee (University of Texas), Hector Bonilla
(Summa Health Systems), Barbara Alexander/Rachel Addison (Duke University),
Marion Tuohy (Cleveland Clinic) and Soo-Hyun Kim (Chonnam National Uni-
versity Medical School) (Supplementary Data 1). Entire or partial MIC and/or Fks
mutational data from Duke University6, CDC11 and S.H. Kim12 (‘miscellaneous’
group) isolates have been previously published. The University Hospital at
Lausanne isolates were all collected between the years of 1993 and 1996, predating
echinocandin clinical use. Hotspots of the FKS1 and FKS2 genes were sequenced in
echinocandin-resistant isolates. PDR1 was sequenced in ﬂuconazole-resistant and
select ﬂuconazole-sensitive isolates from each collection except the Hamad Medical
Corporation isolates. MSH2 was sequenced in all isolates. See Supplementary
Table 3 for primers. Plasmid pGRB2.0 was obtained from Brendan Cormack
(John’s Hopkins University School of Medicine)34. Yeast strains were maintained
in YPD (1% yeast extract, 2% peptone and 2% dextrose) or synthetically-deﬁned
media lacking uracil (SD-ura) or tryptophan (SD-trp) (dropout base plus complete
supplement mixture minus uracil or tryptophan). Plasmid-bearing DH5a E. coli
strain was maintained in 40 mgml 1 ampicillin-supplemented Luria-Bertani (LB)
media. Plasmid-bearing C. glabrata strains (Supplementary Table 4) were
maintained in SD-ura media.
Gene disruption and cloning. C. glabrata ATCC 200989 (2001 HTU) or 2001
HTL (ref. 35) (gift from Karl Kuchler, University of Vienna) was transformed with
a PCR-ampliﬁed TRP1 deletion cassette (see Supplementary Table 3 for primers).
The deletion primers contain ﬂanking regions that are homologous to the
immediate up- and down-stream regions of each target gene’s coding region.
Transformed cells were selected on synthetically-deﬁned media lacking tryptophan,
and colonies were PCR-screened and sequenced to conﬁrm disruption. For
plasmid-based expression of MSH2, a gap-repair approach was used36. Brieﬂy,
coding regions plus promoter regions were PCR-ampliﬁed from laboratory or
clinical isolates with primers (Supplementary Table 3) containing ﬂanking regions
homologous to regions upstream and downstream of the SmaI restriction site in
pGRB2.0. Strain 2001 HTU or msh2D were transformed with this PCR product,
along with SmaI linearized pGRB2.0, and selected on SD-ura media. The resulting
strains are listed in Supplementary Table 4.
Drug susceptibility assays. Fluconazole and echinocandin minimum inhibitory
concentrations (MICs) were determined by broth microdilution following CLSI
standards as described21,22, except for the Qatar isolates, which were analyzed via
Etest methodology according to the manufacturer’s instructions (Lioﬁlchem, Italy).
Fluconazole (LKT Laboratories, Saint Paul, MN), caspofungin (Merck, Rahway,
NJ) and micafungin (Astellas, Deerﬁeld, IL) were dissolved and diluted according
to CLSI standards21. Fluconazole resistance was declared if an isolate demonstrated
a CLSI-deﬁned susceptible dose-dependent (32mgml 1) or resistant
(Z64mgml 1) MIC, while echinocandin resistance was declared if an isolate
demonstrated CLSI-deﬁned resistance to at least two of the three echinocandins
(Z0.5mgml 1 for caspofungin and anidulafungin,Z0.25mgml 1 for micafungin).
Drug selections and mutant analysis. Strains were grown overnight in
appropriate media (YPD or SD-ura) at 37 C. We aimed to plate B1 108 CFU
onto echinocandin-containing drug plates and between 1 105 and 1 106 CFU
onto ﬂuconazole, voriconazole (Pﬁzer), amphotericin B (Sigma-Aldrich,
Milwaukee, WI) and 5-ﬂuoroanthranillic acid (5-FAA, Sigma-Aldrich) plates.
Drug concentrations of mutant selection plates were 16- to 32-fold greater than
the wild type strain MICs. 5-FAA media was prepared as previously described24.
A minimum of three biological replicate selections per strain were performed.
Dilutions were plated onto drug-free media to determine exact CFU counts.
Frequencies were calculated as number of colonies on the drug plate divided by the
total CFU plated. Frequency averages were calculated from at least three
independent selections from the concentration(s) indicated in Table 1. Colonies
were spotted onto plates containing two-fold higher drug concentrations and then
appropriate target genes, for example, FKS1 hotspot 1, FKS2 hotspot 1, PDR1,
ERG6 and TRP5, were PCR-ampliﬁed and sequenced in resistant colonies (see
Supplementary Table 3 for primers).
Colonization mouse model. Six-week-old female CF-1 immunocompetent mice
(Charles River Laboratories) were treated (s.c.) from day -2 to day 6 with
320mg kg 1 PTZ(8:1) to clear native intestinal bacterial ﬂora28. PTZ was then
injected every other day (days 8, 10, 12, 14, 16) and returned to daily injections
near the end of the experiment (days 17–25). On day 0, mice were inoculated via
oral gavage with B1.5 108 CFU of C. glabrata 2001 HTL wild type or isogenic
strain mshD (Supplementary Table 4) in 100 ml of saline. Strain 2001 HTL was
utilized instead of 2001 HTU (ATCC 200989) because the histidine, leucine and
tryptophan auxotrophies do not signiﬁcantly affect the ﬁtness or virulence of
C. glabrata35. Fresh fecal samples were collected throughout the experiment to
assess fungal GI tract colonization. Fungal burden was determined by plating
proper dilutions of fecal samples onto drug-free YPD plates and recorded as
C. glabrata CFU per gram of stool. Daily administration of caspofungin
(0.5mg kg 1) or saline (100 ul i.p.) was initiated on day 6 post inoculation, when
stabilized colonization was observed, and continued through day 26. Colonies on
burden plates were replica-plated onto caspofungin (2 mgml 1) plates and FKS1
and FKS2 hotspots were PCR-ampliﬁed and sequenced in those demonstrating
resistance. Caspofungin-resistant colony frequencies were determined through
selection of fecal samples on YPD plates supplemented with caspofungin
(2 mgml 1), PTZ (16 mgml 1) and chloramphenicol (20 mgml 1). The increased
caspofungin resistant colony frequencies observed with the animal fecal selections
are approximately a 3.7 log increase (5000 ) from the caspofungin selection of the
untreated msh2D strain (compare Fig. 1 with Fig. 3a), allowing us to conclude that
the expanded fks mutant populations within these mice account for that frequency
difference. Nonetheless, replica-plating from drug-free plates was used to uncover
fks mutants to ensure the mutant arose in the animal as opposed to on the plate.
Fitness assays. For the colonization ﬁtness study, mice were colonized as above,
but with an equal mix of C. glabrata 2001 HTL wild type and isogenic strain mshD
totaling 1.5 108 CFU in 100 ml of saline. Control inoculum groups were colonized
with 1.5 108 CFU of a single strain. PTZ treatment was administered daily from
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day -2 to day 11. Fecal samples were collected on days 0, 1, 3, 5, 7, 9 and 11. Plating
of fecal material and CFU counts were performed as stated above. For DNA
extraction, approximately half of the homogenized fecal pellet was subjected to a
2 h incubation with proteinase K (50 mgml 1; Ambion) followed by puriﬁcation
with QIAamp DNA Mini Kit (Qiagen). DNA was isolated from the pellets of each
mouse at each time point. DNA was then subjected to SYBR green quantitative
PCR (qPCR) using strain-speciﬁc primers (Supplementary Table 3) to determine
copy number of each strain within the samples. SYBR green qPCR was performed
on a Mx3005P real-time instrument (Agilent) using Rotor-Gene SYBR Green PCR
kit (Qiagen). The thermal cycling conditions consisted of an initial activation step
at 95 C for 5min and 35 cycles at 95 C for 10 s, and 60 C for 20 s, followed by a
dissociation step at 95 C for 1min, ramping temperature from 55 to 95 C at the
rate of 0.2 C s 1. Speciﬁcity of the primers was conﬁrmed by observing a single
peak in the dissociation curve. The detection limit and ampliﬁcation efﬁciency of
both assays were evaluated by testing 10-fold diluted DNA series (10 ngB100 fg
per reaction) for wild type, msh2D, 10:1 mix of wild type and msh2D, 1:1 mix of
wild type and msh2D, and 1:10 mix of wild type and msh2D. The 1:1 mix of wild
type and msh2D were also used as external standards for strain quantiﬁcation in
each animal sample testing run.
For the systemic infection study, neutropenia was induced in 8-week-old
BALB/c mice (Charles River Laboratories) through administration of 150mg kg 1
cyclophosphamide i.p. on day -4 and 100mg kg 1 on days -1 and day 2 post
infection. Mice were challenged (i.v.) with an equal mix of C. glabrata 2001 HTL
wild type and msh2D totaling 4.0 107 CFU in 100 ml of saline. Control groups
were infected with 4.0 107 CFU of a single strain. On day 3 post infection, mice
were euthanized and kidneys harvested. Half of each kidney was homogenized and
dilutions plated for total CFU counts and the remaining halves were subjected to
DNA isolation as stated above, except with an overnight proteinase K digestion.
DNA was subjected to the same qPCR analysis as the fecal DNAs.
Statistics. All data analyses were performed using GraphPad Prism, version 5.0,
software for Windows (GraphPad Software, San Diego, CA). w2 analysis was used
to determine differences in msh2 mutational status between susceptibility groups.
Differences of resistant frequency between strains were evaluated by Student’s
t-test. A P value of o0.05 (two-tailed) is considered statistically signiﬁcant.
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